NOMURA HOLDINGS INC-SPON ADR (NMR) Stock Fundamental Analysis
NYSE:NMR - New York Stock Exchange, Inc. - US65535H2085 - ADR - Currency: USD
NMR gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 227 industry peers in the Capital Markets industry. NMR has a bad profitability rating. Also its financial health evaluation is rather negative. NMR has a correct valuation and a medium growth rate. NMR also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
NMR had positive earnings in the past year.
NMR had a negative operating cash flow in the past year.
Each year in the past 5 years NMR has been profitable.
The reported operating cash flow has been mixed in the past 5 years: NMR reported negative operating cash flow in multiple years.
1.2 Ratios
NMR has a Return On Assets of 0.48%. This is in the lower half of the industry: NMR underperforms 73.13% of its industry peers.
NMR has a Return On Equity (8.32%) which is in line with its industry peers.
The Return On Invested Capital of NMR (0.49%) is worse than 71.37% of its industry peers.
The Average Return On Invested Capital over the past 3 years for NMR is significantly below the industry average of 7.09%.
The 3 year average ROIC (0.31%) for NMR is below the current ROIC(0.49%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.48% | ||
| ROE | 8.32% | ||
| ROIC | 0.49% |
ROA(3y)0.27%
ROA(5y)0.34%
ROE(3y)4.27%
ROE(5y)5.33%
ROIC(3y)0.31%
ROIC(5y)0.34%
1.3 Margins
NMR's Profit Margin of 5.83% is on the low side compared to the rest of the industry. NMR is outperformed by 70.04% of its industry peers.
In the last couple of years the Profit Margin of NMR has declined.
The Operating Margin of NMR (8.63%) is worse than 70.93% of its industry peers.
In the last couple of years the Operating Margin of NMR has declined.
NMR has a Gross Margin of 37.85%. This is in the lower half of the industry: NMR underperforms 65.64% of its industry peers.
In the last couple of years the Gross Margin of NMR has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.63% | ||
| PM (TTM) | 5.83% | ||
| GM | 37.85% |
OM growth 3Y-22.7%
OM growth 5YN/A
PM growth 3Y-25.03%
PM growth 5YN/A
GM growth 3Y-24.32%
GM growth 5Y-9.19%
2. Health
2.1 Basic Checks
The number of shares outstanding for NMR has been reduced compared to 1 year ago.
Compared to 5 years ago, NMR has less shares outstanding
Compared to 1 year ago, NMR has a worse debt to assets ratio.
2.2 Solvency
NMR has an Altman-Z score of -0.30. This is a bad value and indicates that NMR is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.30, NMR is doing worse than 79.74% of the companies in the same industry.
A Debt/Equity ratio of 11.22 is on the high side and indicates that NMR has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 11.22, NMR is doing worse than 89.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 11.22 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.3 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 0.23 indicates that NMR may have some problems paying its short term obligations.
NMR has a Current ratio of 0.23. This is amonst the worse of the industry: NMR underperforms 86.78% of its industry peers.
NMR has a Quick Ratio of 0.23. This is a bad value and indicates that NMR is not financially healthy enough and could expect problems in meeting its short term obligations.
NMR has a worse Quick ratio (0.23) than 86.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.23 | ||
| Quick Ratio | 0.23 |
3. Growth
3.1 Past
The earnings per share for NMR have decreased strongly by -33.89% in the last year.
Measured over the past years, NMR shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -13.34% on average per year.
NMR shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.50%.
The Revenue has been growing slightly by 4.75% on average over the past years.
EPS 1Y (TTM)-33.89%
EPS 3Y-23.06%
EPS 5Y-13.34%
EPS Q2Q%111.06%
Revenue 1Y (TTM)28.5%
Revenue growth 3Y8.4%
Revenue growth 5Y4.75%
Sales Q2Q%10.75%
3.2 Future
Based on estimates for the next years, NMR will show a very strong growth in Earnings Per Share. The EPS will grow by 35.57% on average per year.
NMR is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.11% yearly.
EPS Next Y78.95%
EPS Next 2Y91.66%
EPS Next 3Y52.3%
EPS Next 5Y35.57%
Revenue Next Year0.68%
Revenue Next 2Y22.72%
Revenue Next 3Y13.7%
Revenue Next 5Y10.11%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 24.77, the valuation of NMR can be described as rather expensive.
Based on the Price/Earnings ratio, NMR is valued a bit more expensive than the industry average as 64.76% of the companies are valued more cheaply.
The average S&P500 Price/Earnings ratio is at 27.63. NMR is around the same levels.
The Price/Forward Earnings ratio is 6.60, which indicates a rather cheap valuation of NMR.
NMR's Price/Forward Earnings ratio is rather cheap when compared to the industry. NMR is cheaper than 90.31% of the companies in the same industry.
NMR is valuated cheaply when we compare the Price/Forward Earnings ratio to 20.85, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.77 | ||
| Fwd PE | 6.6 |
4.2 Price Multiples
69.16% of the companies in the same industry are more expensive than NMR, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 22.45 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NMR's earnings are expected to grow with 52.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.31
PEG (5Y)N/A
EPS Next 2Y91.66%
EPS Next 3Y52.3%
5. Dividend
5.1 Amount
NMR has a Yearly Dividend Yield of 7.16%, which is a nice return.
Compared to an average industry Dividend Yield of 8.41, NMR pays a bit more dividend than its industry peers.
Compared to an average S&P500 Dividend Yield of 2.51, NMR pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 7.16% |
5.2 History
The dividend of NMR is nicely growing with an annual growth rate of 7.29%!
NMR has paid a dividend for at least 10 years, which is a reliable track record.
The dividend of NMR decreased in the last 3 years.
Dividend Growth(5Y)7.29%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
NMR pays out 25.01% of its income as dividend. This is a sustainable payout ratio.
The dividend of NMR is growing, but earnings are growing more, so the dividend growth is sustainable.
DP25.01%
EPS Next 2Y91.66%
EPS Next 3Y52.3%
5.45
-0.05 (-0.91%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners38.98%
Inst Owner Change-0.13%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap16.10B
Analysts69.23
Price Target7.48 (37.25%)
Short Float %0.03%
Short Ratio1.22
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 7.16% |
Yearly Dividend0.15
Dividend Growth(5Y)7.29%
DP25.01%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.6%
PT rev (3m)14.39%
EPS NQ rev (1m)0.89%
EPS NQ rev (3m)24.69%
EPS NY rev (1m)5.52%
EPS NY rev (3m)32.61%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.44%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.77 | ||
| Fwd PE | 6.6 | ||
| P/S | 0.49 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.7 | ||
| P/tB | 0.7 | ||
| EV/EBITDA | 22.45 |
EPS(TTM)0.22
EY4.04%
EPS(NY)0.83
Fwd EY15.16%
FCF(TTM)-3.03
FCFYN/A
OCF(TTM)-0.32
OCFYN/A
SpS11.18
BVpS7.83
TBVpS7.76
PEG (NY)0.31
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.48% | ||
| ROE | 8.32% | ||
| ROCE | 1.45% | ||
| ROIC | 0.49% | ||
| ROICexc | 0.54% | ||
| ROICexgc | 0.55% | ||
| OM | 8.63% | ||
| PM (TTM) | 5.83% | ||
| GM | 37.85% | ||
| FCFM | N/A |
ROA(3y)0.27%
ROA(5y)0.34%
ROE(3y)4.27%
ROE(5y)5.33%
ROIC(3y)0.31%
ROIC(5y)0.34%
ROICexc(3y)0.34%
ROICexc(5y)0.37%
ROICexgc(3y)0.34%
ROICexgc(5y)0.38%
ROCE(3y)0.89%
ROCE(5y)1.01%
ROICexcg growth 3Y-3.29%
ROICexcg growth 5YN/A
ROICexc growth 3Y-3.32%
ROICexc growth 5YN/A
OM growth 3Y-22.7%
OM growth 5YN/A
PM growth 3Y-25.03%
PM growth 5YN/A
GM growth 3Y-24.32%
GM growth 5Y-9.19%
F-Score5
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 11.22 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 78.89 | ||
| Cap/Depr | 1824.53% | ||
| Cap/Sales | 24.27% | ||
| Interest Coverage | 0.14 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.23 | ||
| Quick Ratio | 0.23 | ||
| Altman-Z | -0.3 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)580.51%
Cap/Depr(5y)450.89%
Cap/Sales(3y)10.9%
Cap/Sales(5y)10.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-33.89%
EPS 3Y-23.06%
EPS 5Y-13.34%
EPS Q2Q%111.06%
EPS Next Y78.95%
EPS Next 2Y91.66%
EPS Next 3Y52.3%
EPS Next 5Y35.57%
Revenue 1Y (TTM)28.5%
Revenue growth 3Y8.4%
Revenue growth 5Y4.75%
Sales Q2Q%10.75%
Revenue Next Year0.68%
Revenue Next 2Y22.72%
Revenue Next 3Y13.7%
Revenue Next 5Y10.11%
EBIT growth 1Y94.33%
EBIT growth 3Y5.89%
EBIT growth 5YN/A
EBIT Next Year34467.3%
EBIT Next 3Y600.45%
EBIT Next 5YN/A
FCF growth 1Y33.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y92.55%
OCF growth 3Y-49.33%
OCF growth 5YN/A